BlossomHill Therapeutics Announces Updated Phase 1/2 SOLARA Data On BH-30643 In EGFR-Mutant NSCLC With Secondary Resistance Mutations To Be Presented September 15 At World Conference On Lung Cancer

Loading news article.

BlossomHill Therapeutics Announces Updated Phase 1/2 SOLARA Data On BH-30643 In EGFR-Mutant NSCLC With Secondary Resistance Mutations To Be Presented September 15 At World Conference On Lung Cancer | WAPE

BlossomHill Therapeutics Announces Updated Phase 1/2 SOLARA Data On BH-30643 In EGFR-Mutant NSCLC With Secondary Resistance Mutations To Be Presented September 15 At World Conference On Lung Cancer

Article summary

Related companies

Comments —